Abstract
Natural products are generally accepted by most industrial drug research organisations, but despite their incredible sustained track record and contribution to the pharmaceutical industries' revenue streams, they are not fully appreciated. An improved integration of natural products into state-of-the-art drug research processes is only one of the options available. What changes must be made to improve the exploitation of nature's diversity and where might natural products play a dominant role?